

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

Recombinant Anti-IL-1 beta antibody [EPR24895-116]

RRID:AB_3105874

Type: Antibody

Proper Citation

Abcam Cat# ab315084, RRID:AB_3105874

Antibody Information

URL: http://antibodyregistry.org/AB_3105874

Proper Citation: Abcam Cat# ab315084, RRID:AB_3105874

Target Antigen: IL-1 beta

Host Organism: Rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-P, ICC/IF, Flow Cyt (Intra), WB

Antibody Name: Recombinant Anti-IL-1 beta antibody [EPR24895-116]

Description: This recombinant monoclonal targets IL-1 beta

Target Organism: rat, mouse, human

Clone ID: EPR24895-116

Antibody ID: AB_3105874

Vendor: Abcam

Catalog Number: ab315084

Record Creation Time: 20250819T232515+0000

Record Last Update: 20250820T051711+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-IL-1 beta antibody [EPR24895-116].

No alerts have been found for Recombinant Anti-IL-1 beta antibody [EPR24895-116].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Dong X, et al. (2026) Synthetic cleavage-resistant TREM2 boosts macrophage efferocytosis to treat inflammatory diseases. Cell reports. Medicine, 7(2), 102580.

Shen H, et al. (2025) Reactive oxygen species-responsive hydrogel loaded with melatonin as a minimally invasive treatment for myocardial I/R injury. iScience, 28(7), 112834.

Chen W, et al. (2025) Static magnetic fields alleviate diabetic nephropathy by reducing renal cell inflammation and promoting M2??macrophage polarization. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 39(5), e70424.

Cai Y, et al. (2024) Melatonin alleviates high-fat-diet-induced dry eye by regulating macrophage polarization via IFT27 and lowering ERK/JNK phosphorylation. iScience, 27(7), 110367.